Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sawai Chalks Up More Than A Dozen Launches

Follows Approvals From Japan's MHLW Earlier This Year

Executive Summary

Sawai has followed-up on a raft of approvals announced earlier this year with launch plans, including for the first generics of Daiichi Sankyo’s Memary (memantine hydrochloride) Alzheimer’s disease treatment in three presentations.

You may also be interested in...



Sawai’s Upsher-Smith Takes Aim At US Corticotropin Opportunity

Upsher-Smith Laboratories, the US arm of Japan’s Sawai Pharmaceutical, has another challenging project in the pipeline with an agreement to develop and market a follow-on version of Mallinckrodt’s Acthar Gel (corticotropin). The Japanese firm revealed Upsher-Smith’s latest finances as it revealed first-quarter financial results.

Eldecalcitol Challenge Filed In Japan

Sawai and Nichi-Iko are in the crosshairs of Chugai after the originator filed a lawsuit in Japan claiming patent infringement over the pair’s generic eldecalcitol versions of its Edirol brand.

Japan’s Sawai Forecasts Sales Milestone This Year

Sales growth through new product launches and increasing the value of its current portfolio will allow Sawai to increase sales by around a tenth this year, the Japanese firm has forecasted, as it also revealed full-year financials for the 12 months ended 31 March 2020.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel